GlassScriptPhysician profile
Decontee Jimmeh
NPI 1366659229
$8,372.04
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $7,306 · 2022: $56.74.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,036.28 | 2019-2020 | |
| Amgen INC. | $151.35 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $131.84 | 2019-2020 | |
| Lilly USA, LLC | $114.52 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $109.59 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $106.74 | 2019-2020 | |
| Tersera Therapeutics LLC | $81.56 | 2019 | |
| Avanir Pharmaceuticals, INC. | $68.87 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $65.65 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $62.77 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $59.14 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $51.76 | 2019 | |
| Daiichi Sankyo INC. | $41.75 | 2019 | |
| Acorda Therapeutics, INC | $37.30 | 2019 | |
| Sunovion Pharmaceuticals INC. | $35.85 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $26.96 | 2019 | |
| Mdd US Operations, LLC | $26.64 | 2019 | |
| Akcea Therapeutics, INC. | $25.27 | 2019 | |
| Nevro Corp. | $24.14 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.66 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.92 | 2019 | |
| Neurocrine Biosciences, INC. | $16.90 | 2020 | |
| Forte Bio-Pharma LLC | $14.22 | 2020 | |
| Flowonix Medical Incorporated | $13.41 | 2020 | |
| Zyla Life Sciences, INC. | $12.13 | 2020 | |
| Assertio Therapeutics, INC. | $11.71 | 2019 | |
| Promius Pharma LLC | $11.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Decontee Jimmeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.